Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — Q3 2026 Earnings Presentation
15 slides from Neurocrine Biosciences's earnings presentation, Nov 2, 2026
Slide 1: Q3 2026 Earnings Presentation
Q3 2026 Earnings Presentation Neurocrine Biosciences (Nasdaq: NBIX) November 2, 2026 1
Slide 2: Safe Harbor and Forward-Looking Statements
Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our business strategy, objectives, and future d
Slide 3: Neurocrine Well-Positioned to Drive Sustainable Growth and Value
Neurocrine Well-Positioned to Drive Sustainable Growth and Value COMMERCIAL* RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION ,1 • Neuropsychiatry INGREZZA TARDIVE DYSKINESIA & Therapeutic Area 2026 FY Net Sales Guidance Range HUNTINGTON’S • Endocrinology Diversification Raised to $2.9 - $2.925 Bill
Slide 4: Delivering Strong and Diversified Growth with Over $1.1 Billion in Q3 2026 Net Sales
Delivering Strong and Diversified Growth with Over $1.1 Billion in Q3 2026 Net Sales Across INGREZZA, CRENESSITY and VYKAT XR $ Millions +43% 1,200 $1,119 1,100 107 1,000 $954 54 * 28% 900 211 $785 $793 $810 800 184 98 135 153 700 600 500 400 801 72% 687 716 658 657 300 200 100 0 Q3 2025 Q4 2025 Q1
Slide 5: Advancing Industry-Leading Pipeline With Multiple Important Clinical Milestones in 2027
Advancing Industry-Leading Pipeline With Multiple Important Clinical Milestones in 2027 2026 New Study Initiations / Updates 2027 Study Data Readouts 4 New Phase 2 Programs Initiated: Phase 3 • NBI-’567 (M1 Preferring Agonist for Alzheimer’s Disease Cognition) • Osavampator (AMPA PAM for Major Depre
Slide 6: Robust Pipeline Advancing Through 2026
Robust Pipeline Advancing Modality Key: Small Molecule Peptide Antibody Gene Therapy Through 2026 Therapeutic Area Key: Neuropsychiatry Endocrinology Immunology Smart and Strategic Diversification Study Initiating in 2026 Phase 1 Phase 2 Phase 3 NBIB-’223 (Frataxin) NBI-’569* (M1/M4 Agonist) direcli
Slide 7: Q3 2026 Financial Results
Q3 2026 Financial Results 7
Slide 8: Q3 2026 Financial Summary
Q3 2026 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q3 2026 Q3 2025 Highlights / Comments Total Revenue Grew 41% YoY Revenue $1,123 $795 INGREZZA Sales Grew 17% YoY Driven by Double-Digit Volume Growth, with Record Total - INGREZZA Net Product Sales $801 $687 and New Prescr
Slide 9: 2026 INGREZZA Net Sales Guidance Raised to $2.9 to $2.925 Billion
2026 INGREZZA Net Sales Guidance Raised to $2.9 to $2.925 Billion Prior Updated Item ($ Millions) 2025 Actuals 2026 Guidance 2026 Guidance INGREZZA Net Product Sales1 $2,514 $2,825 - $2,875 $2,900 - $2,925 GAAP R&D Expense2 $1,016 $1,275 - $1,325 No Change Non-GAAP R&D Expense2,3 $925 $1,140 - $1,19
Slide 10: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 10
Slide 11: Condensed Consolidated Statements of Income
NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in millions, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025 Revenues: Net product sales S$ 1119.0 $ 789.9 $ 2,884.3 $ 2,035.6 Collaboration revenues 37 5.
Slide 12: Condensed Consolidated Balance Sheets
g CONDENSED CONSOLIDATED BALANCE SHEETS NEUROCRINE BIOSCIENCES, INC. (unaudited, in millions) Cash, cash equivalents, and marketable securities Accounts receivable Inventory Other current assets Total current assets Noncurrent inventory Noncurrent marketable securities Right-of-use assets Equity inv
Slide 13: Reconciliation of GAAP to Non-GAAP Financial Results
NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited, in millions, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025 GAAP net income ! $ 2065 $ 2095 $ 548.8 $ 324.9 Adjustments: Stock-based compensation
Slide 14: Reconciliation of GAAP to Non-GAAP Financial Results
‘NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON.GAAP FINANCIAL RESULTS (unaudited, in millions) ‘Sipember 0, Cost of Revenues GAAP cost of revenues S w6ES 0S OSs HS Adjustments: Acceleration of stock: based compensation expense and related taxes - - 18 - -Acquisition-relared employee com
Slide 15: Q3 2026 Earnings Presentation
Q3 2026 Earnings Presentation Neurocrine Biosciences (Nasdaq: NBIX) November 2, 2026
Neurocrine Biosciences — Q3 2026 Earnings Presentation on 6ix